KDR and Miyoshi myopathy: We conducted a phase Ib combination study of axitinib, a VEGFR tyrosine kinase inhibitor, with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1, to treat patients with metastatic MM (ClinicalTrials.gov).20 This was the first study testing the combination of immunotherapy and VEGFR-targeting therapy in treatment-naïve patients with advanced MM.